Biologic and Small Molecule Therapy Switch in Atopic Dermatitis Patients with Dupilumab-Associated Ocular Surface Disease: A Systematic Review

Abstract

Keywords

atopic dermatitis ocular surface disease dupilumab dupilumab-associated ocular surface disease Janus Kinase inhibitors biologics treatment therapeutic systematic review

Get full access to this article

View all access options for this article.

References

Schlösser

Bult

Thelen

, et al. Higher prevalence of dupilumab-induced ocular adverse events in atopic dermatitis compared to asthma: a daily practice analysis. Clin Trans Allergy. 2024;14(8):e12386. doi:10.1002/clt2.12386

Shim

Kim

Yee

Gwak

HS.

A risk-scoring system to predict dupilumab-associated ocular surface disease in patients with atopic dermatitis. Front Pharmacol. 2024;15:1425550. doi:10.3389/fphar.2024.1425550

Achten

Dekkers

Bakker

, et al. (2023). Switching from dupilumab to tralokinumab in atopic dermatitis patients with ocular surface disease: preliminary case series. Clin Exper Allergy 2023;53(5):586-589. doi:10.1111/cea.14305

Wollenberg

Beck

de Bruin Weller

, et al. (2022). Conjunctivitis in adult patients with moderate-to-severe atopic dermatitis: results from five tralokinumab clinical trials. Br J Dermatol. 2022;186(3);453-465. doi:10.1111/bjd.20810

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.03 MB

0.02 MB

0.00 MB

0.03 MB